Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Inspire Medical Systems ( (INSP) ) is now available.
Inspire Medical Systems announced preliminary, unaudited results for the fourth quarter and full year 2024, reporting a 25% year-over-year revenue growth in the fourth quarter and 28% for the full year. The company also provided initial 2025 revenue guidance, projecting a 17% to 19% increase over 2024. The company highlighted strategic organizational changes, including new leadership appointments, to support continued growth and increased adoption of their neurostimulation therapy. The company is optimistic about the future, emphasizing a strong position to fuel growth and deliver value to stakeholders.
More about Inspire Medical Systems
Inspire Medical Systems is a medical technology company that develops and commercializes innovative, minimally invasive solutions for patients with obstructive sleep apnea. Their proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology of its kind, providing a safe and effective treatment for moderate to severe obstructive sleep apnea.
YTD Price Performance: 7.02%
Average Trading Volume: 496,520
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.07B
Learn more about INSP stock on TipRanks’ Stock Analysis page.
